Dutch medical equipment supplier Vitestro has launched Aletta, an autonomous robotic phlebotomy device designed to transform blood collection with precision and consistency.
The robotic phlebotomy device is named after Dr. Aletta Jacobs, the female doctor in the Netherlands who made significant contributions to healthcare.
Aletta introduces a new category of medical robotics, and its design focuses on optimising blood collection, setting a global benchmark for automated venous blood draws.
It aims to advance medical robotics by enhancing the efficiency and safety of blood draws.
Also, it improves clinical precision, safety, and patient experience, while mitigating healthcare staffing shortages by allowing medical staff to focus more on patient care.
Vitestro co-founder and commercial director Brian Joseph said: “The name Aletta fosters a human connection with both healthcare professionals and patients – making Aletta more than just technology.
“Patients and healthcare staff will interact with Aletta every day, and we want them to see her as an integral part of the phlebotomy team.
“By working alongside trained medical personnel, Aletta enhances precision and efficiency, ensuring a seamless experience and the highest quality of care for every patient.”
Aletta features advanced capabilities, including AI-powered Doppler ultrasound and imaging technology for accurate vein identification.
Its robotic-controlled needle insertion ensures consistent and precise blood draws, while fully automated blood collection reduces variability and reliance on human intervention.
The device easily integrates into hospital and laboratory workflows, enhancing efficiency and patient throughput.
Also, it is clinically validated for safety and comfort, being tested on more than four thousand patients, with pain levels comparable to or lower than manual blood draws.
Following its CE-mark approval and initial launch in Europe, Vitestro is preparing for wider adoption across the region.
The company is also pursuing US regulatory approval and conducting a multi-centre clinical trial with leading academic medical centres in the US.
